Demand for Medicine Propels Merck KGaA Profit

Demand for Medicine Propels Merck KGaA Profit Play

Merck KGaA, the German maker of the cancer drug Erbitux, raised its full year forecast after second-quarter profit rose 14 percent as the euro’s decline boosted sales and demand for medicines increased.

  • On Air Now

    Charlie Rose Watch Now

  • Next

    Bloomberg West

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus